New device aims to improve safety in heart valve replacement

NCT ID NCT07205341

Recruiting now Knowledge-focused Sponsor: HemoCept Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study is testing a new device called HemoCept that measures blood volume and heart efficiency during trans-aortic valve replacement (TAVR) surgery for aortic stenosis. The study will enroll 20 adults aged 18-80 who need TAVR. Researchers want to see if the device's readings match standard heart measurements taken before and after the procedure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HemoCept device
What this could lead to: If successful, this could lead to a new way to monitor blood volume and heart function during TAVR surgery, potentially improving patient safety.
What could go wrong: This is a very small pilot study with only 20 people, so results may not apply to everyone. The device is still experimental and may not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AORTIC VALVE STENOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aortic valve stenosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AORTIC VALVE STENOSIS

Contacts and locations

Locations

Boulder Heart
RECRUITING

Boulder, Colorado, 80303, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.